UPB
NASDAQ HealthcareUpstream Bio, Inc. - Common Stock
Biotechnology
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
๐ Market Data
| Price | $9.40 |
|---|---|
| Volume | 476,105 |
| Market Cap | 511.55M |
| RSI (14-Day) | 36.7 |
| 200-Day MA | $18.87 |
| 50-Day MA | $9.03 |
| 52-Week High | $33.68 |
| 52-Week Low | $7.25 |
| Forward P/E | -2.91 |
| Price / Book | 1.50 |
๐ฏ Investment Strategy Scores
UPB scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (99/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Over-Hyped (11/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find UPB in your text
Paste any article, transcript, or post โ the tool will extract UPB and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.